基于美国FAERS数据库的利拉鲁肽和司美格鲁肽不良事件信号挖掘与分析

doi:10.19803/j.1672-8629.20240753

摘要/Abstract

摘要： 目的挖掘对比利拉鲁肽、司美格鲁肽上市后的不良事件信号,为临床安全用药提供参考。方法采用报告比值比（Reporting Odds Ratio,ROR）法,比例报告比值比（Proportional Reporting Ratio,PRR）法,信息成分（Information Component,IC）法及多项伽马-泊松分布缩减（Muti-item Gamma Poisson Shrinker,MGPS）法,对美国食品药品监督管理局（Food and Drug Administration, FDA）不良事件报告系统（Adverse Event Reporting System, FAERS）数据库中,2010年1月1日至2024年3月31日利拉鲁肽及司美格鲁肽的不良事件数据进行挖掘,筛选阳性及肿瘤相关信号进行对比分析。结果利拉鲁肽共挖掘得到阳性信号175个,涉及20个系统-器官分类（SOC）。司美格鲁肽共挖掘得到231个阳性信号,涉及21个SOC。两者不良事件均主要涉及胃肠系统和代谢及营养类疾病。肿瘤方面,均以甲状腺及胰腺相关肿瘤为主,且肿瘤相关不良事件发生的最大占比时间均位于大于360 d时间段。利拉鲁肽与甲状腺肿瘤、胰腺肿瘤及胰腺炎相关不良事件的关联性更强且累及病例数量更多。司美格鲁肽在痛觉、皮肤等感觉异常及眼器官相关不良事件方面更为突出。结论利拉鲁肽和司美格鲁肽在药品不良反应方面具有一定的共性及特性,临床可根据药物特点及患者基础情况,进行个性化选择用药。同时,建议相关说明书对的可能性给予一定的警示或说明。

关键词: 利拉鲁肽, 司美格鲁肽, 美国FAERS数据库, 报告比值比, 比例报告比值比, 信息成分法, 多项伽马-泊松分布缩减法, 胰腺肿瘤, 药品不良事件

Abstract: Objective To mine and compare signals of post-marketing adverse events of liraglutide and semaglutide in order to provide references for safe and rational use. Methods Data on adverse events reported by the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) between January 1, 2010 and March 31, 2024 was mined using the reporting odds ratio (ROR) method, proportional reporting ratio (PRR) method, information component (IC) method, and the muti-item gamma poisson shrinker (MGPS) method. Positive signals and tumor related signals were screened out and compared. Results 175 positive signals related to liraglutide were mined, involving 20 systems organs class (SOC), compared with 231 for semaglutide, involving 21 SOC. The adverse events manifested themselves as gastrointestinal disorders, metabolism and nutrition disorders. In terms of tumors, thyroid and pancreatic related tumors were dominating and onset of symptoms in most of the cases was after 360 days. Liraglutide was more significantly correlated with such adverse events as thyroid tumors, pancreatic tumors, and pancreatitis while semaglutide was likely to cause adverse events related to eyes and the skin. Conclusion Liraglutide and semaglutide can cause similar adverse drug reactions, so clinicians are advised to opt for personalized medications while warnings about the possibility of pancreatic tumors should be given in related instructions.

Key words: Liraglutide, Semaglutide, FAERS Databases, Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Information Component (IC), Muti-Item Gamma Poisson Shrinker (MGPS), Pancreatic Tumors, Adverse Drug Events

中图分类号:

R798.1
R743

钟玲, 曾慧妍, 袁鑫, 王颖彦. 基于美国FAERS数据库的利拉鲁肽和司美格鲁肽不良事件信号挖掘与分析[J]. 中国药物警戒, 2025, 22(3): 305-312.

ZHONG Ling, ZENG Huiyan, YUAN Xin, WANG Yingyan. Adverse Event Signals of Liraglutide and Semaglutide Based on the FAERS Database[J]. Chinese Journal of Pharmacovigilance, 2025, 22(3): 305-312.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://zgywjj.magtechjournal.com/CN/10.19803/j.1672-8629.20240753

https://zgywjj.magtechjournal.com/CN/Y2025/V22/I3/305

参考文献

[1] National Health Commission Disease Control and Prevention Bureau. Report on the Nutrition and Chronic Disease Status of Chinese Residents
(2020)(中国居民营养与慢性病状况报告(2020)[M] 2020)(中国居民营养与慢性病状况报告(2020)[M].Beijing: People's Medical Publishing House, 2021.
[2] Chinese Diabetes Society, National Office for Primary Diabetes Care. National Handbook for the Prevention and Control of Diabetes in Primary Care(2022)[J].Chinese Journal of Internal Medicine(中华内科杂志),2022, 61(3): 249-262.
[3] NAKHLA M, NAIR A, BALANI P, et al.Risk of Suicide, Hair Loss, and Aspiration with GLP1-Receptor Agonists and Other Diabetic Agents: a Real-World Pharmacovigilance Study[J].Cardiovascular Drugs and Therapy, 2024, 9: 1-11.
[4] HE L, LI Q, YANG Y, et al.Pharmacovigilance Study of GLP-1 Receptor Agonists for Metabolic and Nutritional Adverse Events[J].Frontiers in Pharmacology, 2024, 15: 1416985-1416998.
[5] SI HJ, ZHAO LM, CAI S, et al.Medication Guidelines for Glucagon-Like Peptide-l Receptor Agonist(2023 Edition)[J].China Pharmacy(中国药房),2023, 34(11): 1281-1292.
[6] HANSSEN R, RIGOUX L, KUZMANOVIC B, et al.Liraglutide Restores Impaired Associative Learning in Individuals with Obesity[J].Nature Metabolism, 2023, 5(8): 1352-1363.
[7] XIE ZY, HUANG SY, HU X, et al. Clinical Comprehensive Evaluation of 6 GLP-1RAs for the Treatment of Type 2 Diabetes Mellitus[J/OL].Chin J Hosp Pharm(中国医院药学杂志),(2024-09-29)[2024-10-11].https://link.cnki.net/urlid/42.1204.R.20240929.1245.002.
[8] YANG Q, WANG J, WANG M, et al.Stratified Analysis of the Association between Anti-Obesity Medications and Digestive Adverse Events: a Real-World Study Based on the FDA Adverse Event Reporting System Database[J].BMC Pharmacology and Toxicology, 2024, 25(1): 64-76.
[9] ALENZI K A, ALSUHAIBANI D, BATARFI B, et al.Pancreatitis with Use of New Diabetic Medications: a Real-World Data Study Using The Post-Marketing FDA Adverse Event Reporting System(FAERS) Database[J].Frontiers in Pharmacology, 2024, 15: 1364110-1364120.
[10] BHATTACHARYYA M, MILLER LE, MILLER AL, et al.Mortality and Serious Adverse Events Associated with Glucagon-Like Peptide-1 Receptor Agonists: a Pharmacovigilance Study Using the FDA Adverse Event Reporting System[J].Cureus, 2024, 16(8): e65989-e65998.
[11] ZHOU RS, LU PW, CHEN JH, et al.Application of Adverse Drug Reaction of Data Mining in Pharmacovigilance[J].Chin J Mod Appl Pharm(中国现代应用药学) , 2024, 41(6): 864-870.
[12] DONG S, SUN C.Can Glucagon-Like Peptide-1 Receptor Agonists Cause Acute Kidney Injury? An Analytical Study Based on Post-Marketing Approval Pharmacovigilance Data[J].Front Endocrinol(Lausanne),2022, 13: 1032199-1032209.
[13] JIANG Y, ZHOU L, SHEN Y, et al.Safety Assessment of Brexpiprazole: Real-World Adverse Event Analysis from the FAERS Database[J].Journal of Affective Disorders, 2024, 346: 223-229.
[14] VAN PUIJENBROEK EP, DIEMONT WL, VAN GROOTHEEST K.Application of Quantitative Signal Detection in the Dutch Spontaneous Reporting System for Adverse Drug Reactions[J].Drug Safety, 2003, 26(5): 293-301.
[15] BELLIDO D, ABELLAN P, PALOMAR JMR, et al.Intensification of Basal Insulin Therapy with Lixisenatide in Patients with Type 2 Diabetes in a Real-World Setting: the BASAL-LIXI Study[J].Current Therapeutic Research, 2018, 89: 37-42.
[16] GORGOJO-MARTINEZ JJ, MEZQUITA-RAYA P, CARRETERO-GOMEZ J, et al.Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: a Multidisciplinary Expert Consensus[J].Journal of Clinical Medicine, 2022, 12(1): 145-162.
[17] REHFELD JF, KNOP FK, ASMAR M.Gastrin Secretion in Normal Subjects and Diabetes Patients is Inhibited by Glucagon-Like Peptide 1: a Role in the Gastric Side Effects of GLP-1-Derived Drugs?[J].Scandinavian Journal of Gastroenterology, 2019, 54(12): 1448-1451.
[18] LIU L, CHEN J, WANG L, et al.Association between Different GLP-1 Receptor Agonists and Gastrointestinal Adverse Reactions: a Real-World Disproportionality Study Based on FDA Adverse Event Reporting System Database[J].Frontiers in Endocrinology, 2022, 13: 1043789-1043799.
[19] Pharmaceuticals and Medical Devices Agency. Summary of Investigation Results Preparations Containing GLP-1 Receptor Agonists and Tirzepatide[EB/OL].(2023-02-14)[2024-04-14].https://www.pmda.go.jp/files/000250523.
[20] HE L, WAND J, PING F, et al.Association of Glucagon-Like Peptide-1 Receptor Agonist Use with Risk of Gallbladder and Biliary Diseases: a Systematic Review and Meta-Analysis of Randomized Clinical Trials[J].JAMA Internal Medicine, 2022, 182(5): 513-519.
[21] AYOUB WA, KUMAR AA, NAGUIB HS, et al.Exenatide-Induced Acute Pancreatitis[J].Endocrine Practice, 2010, 16(1): 80-83.
[22] BUTLER ADE, CAMPBELL-THOMPSON M, GURLO T, et al.Marked Expansion of Exocrine and Endocrine Pancreas with Incretin Therapy in Humans with Increased Exocrine Pancreas Dysplasia and the Potential for Glucagon-Producing Neuroendocrine Tumors[J].Diabetes, 2013, 62(7): 2595-2604.
[23] BUTLER PC, ELASHOFF M, ELASHOFF R, et al.A Critical Analysis of the Clinical Use of Incretin-Based Therapies: Are the GLP-1 Therapies Safe?[J].Diabetes Care, 2013, 36(7): 2118-2125.
[24] NAUCK MA.A Critical Analysis of the Clinical Use of Incretin Based Therapies: the Benefits by Far Outweigh the Potential Risks[J].Diabetes Care, 2013, 36(7): 2126-2132.
[25] DENG H, YANG F, MA X, et al.Long-Term Liraglutide Administration Induces Pancreas Neogenesis in Adult T2DM Mice[J].Cell Transplantation,2020, 29: 0963689720927392-0963689720927407.
[26] BEZIN J, GOUVERNEUR A, PENICHON M, et al.GLP-1 Receptor Agonists and the Risk of Thyroid Cancer[J].Diabetes Care, 2023, 46(2): 384-390.
[27] YANG Z, LV Y, YU M, et al.GLP-1 Receptor Agonist-Associated Tumor Adverse Events: a Real-World Study from 2004 to 2021 Based on FAERS[J].Frontiers in Pharmacology, 2022, 13: 925377-925387.
[28] JENSTERLE M, RIZZO M, HALUZIK M, et al.Efficacy of GLP-1 RA Approved for Weight Management in Patients with or without Diabetes: a Narrative Review[J].Advances in Therapy, 2022, 39(6): 2452-2467.
[29] WILDING JPH.Medication Use for the Treatment of Diabetes in Obese Individuals[J].Diabetologia, 2018, 61(2): 265-272.
[30] CDR, NMPA. Pharmacovigilance flash: UK Warns That Risk of Diabetes Ketoacidosis Caused by Combination of GLP-1 RA and Insulin[EB/OL].(2019-07-29)[2024-04-14].https://cdr.adr.org.cn/drug_1/aqjs_1/drug_aqjs_jjkx/201907/t20190729_46676.html.
[31] ABCOUWER SF, GARDNER TW.Diabetic Retinopathy: Loss of Neuroretinal Adaptation to the Diabetic Metabolic Environment[J].Annals of the New York Academy of Sciences, 2014, 1311(1): 174-190.
[32] HOLSCHER C.Potential Role of Glucagon-Like Peptide-1(GLP-1) in Neuroprotection[J].CNS Drugs, 2012, 26(10): 871-882.
[33] ZHENG D, LI N, HOU R, et al.Glucagon-Like Peptide-1 Receptor Agonists and Diabetic Retinopathy: Nationwide Cohort and Mendelian Randomization Studies[J].BMC Medicine, 2023, 21(1): 40-50.
[34] VARADHAN L, HUMPHREYS T, WALKER AB, et al.The Impact of Improved Glycaemic Control with GLP-1 Receptor Agonist Therapy on Diabetic Retinopathy[J].Diabetes Research and Clinical Practice, 2014, 103(3): 37-39.
[35] SUN YX, LIU XH, YANG M, et al.Data Mining for Adverse Reaction Signals of Fluoroquinolones in Children Based on the FAERS Database[J].Chin J Hosp Pharm(中国医院药学杂志),2023, 43(17): 1943-1948.